主要终点-话题@MedSci

#主要终点#

97篇内容 | 2632人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1996943, encodeId=154f19969434e, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=ImmunoGen的抗体 - 药物偶联物Mirvetuximab soravtansine未达到III期卵巢癌研究的主要终点, objectType=article, longId=161544, objectId=4fbf1615443f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fbf1615443f, replyNumber=0, likeNumber=78, createdTime=2019-03-03, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fbf1615443f, moduleTitle=ImmunoGen的抗体 - 药物偶联物Mirvetuximab soravtansine未达到III期卵巢癌研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fbf1615443f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996937, encodeId=17cc199693e7b, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=NEJM：无转移生存可以作为前列腺癌新药审批的主要终点(SPARTAN研究), objectType=article, longId=142293, objectId=9492142293cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9492142293cf, replyNumber=0, likeNumber=72, createdTime=2019-01-10, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9492142293cf, moduleTitle=NEJM：无转移生存可以作为前列腺癌新药审批的主要终点(SPARTAN研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9492142293cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996941, encodeId=6b0619969414b, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Vertex制药表示VX-659三联疗法治疗囊肿性纤维化的III期研究达到了主要终点, objectType=article, longId=154586, objectId=9b231545869e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b231545869e, replyNumber=0, likeNumber=68, createdTime=2019-09-30, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b231545869e, moduleTitle=Vertex制药表示VX-659三联疗法治疗囊肿性纤维化的III期研究达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b231545869e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996940, encodeId=3d92199694063, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=阿斯利康狼疮药物anifrolumab未能到达三期临床试验的主要终点, objectType=article, longId=148032, objectId=3e5614803226, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e5614803226, replyNumber=0, likeNumber=66, createdTime=2018-12-23, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e5614803226, moduleTitle=阿斯利康狼疮药物anifrolumab未能到达三期临床试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e5614803226)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996938, encodeId=886a1996938fe, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=RedHill的RHB-104完成了克罗恩病治疗的主要终点, objectType=article, longId=145541, objectId=b0541455415a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0541455415a, replyNumber=0, likeNumber=68, createdTime=2019-02-17, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0541455415a, moduleTitle=RedHill的RHB-104完成了克罗恩病治疗的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0541455415a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996939, encodeId=09f419969393f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=大冢制药的guadecitabine未达到一线治疗AML的III期研究的主要终点, objectType=article, longId=145679, objectId=d3dd1456e979, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3dd1456e979, replyNumber=0, likeNumber=64, createdTime=2018-08-11, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3dd1456e979, moduleTitle=大冢制药的guadecitabine未达到一线治疗AML的III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3dd1456e979)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996936, encodeId=c3a2199693667, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Keytruda治疗头颈癌三期临床试验未达主要终点(Keynote-040研究), objectType=article, longId=106852, objectId=5c6a10685217, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c6a10685217, replyNumber=0, likeNumber=88, createdTime=2018-05-26, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c6a10685217, moduleTitle=Keytruda治疗头颈癌三期临床试验未达主要终点(Keynote-040研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c6a10685217)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996935, encodeId=e1a11996935c3, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=膀胱癌药物3期临床达主要终点, objectType=article, longId=100370, objectId=138c1003e005, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=138c1003e005, replyNumber=0, likeNumber=103, createdTime=2018-01-18, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=138c1003e005, moduleTitle=膀胱癌药物3期临床达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=138c1003e005)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996934, encodeId=eeae1996934c9, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点, objectType=article, longId=85558, objectId=25048555835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25048555835, replyNumber=0, likeNumber=79, createdTime=2017-08-03, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25048555835, moduleTitle=辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25048555835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996932, encodeId=ec2a19969325c, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=阿斯利康复方抗生素Zavicefta达医院获得性肺炎III期临床主要终点, objectType=article, longId=73929, objectId=f3abe392977, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3abe392977, replyNumber=0, likeNumber=66, createdTime=2016-10-05, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3abe392977, moduleTitle=阿斯利康复方抗生素Zavicefta达医院获得性肺炎III期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3abe392977)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996933, encodeId=8df719969337b, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=艾滋病新复方药3期临床试验达主要终点, objectType=article, longId=85189, objectId=47ed85189ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47ed85189ef, replyNumber=0, likeNumber=60, createdTime=2017-11-08, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47ed85189ef, moduleTitle=艾滋病新复方药3期临床试验达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47ed85189ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996930, encodeId=1ef11996930c9, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=阿斯利康心血管药Brilinta未能达到新适应症III期临床主要终点, objectType=article, longId=65585, objectId=4f7365585cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f7365585cc, replyNumber=0, likeNumber=74, createdTime=2017-02-27, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f7365585cc, moduleTitle=阿斯利康心血管药Brilinta未能达到新适应症III期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f7365585cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996931, encodeId=5b921996931bf, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=诺华抗癌药Jakavi达真性红细胞增多症III期临床主要终点, objectType=article, longId=71290, objectId=e56ee129027, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e56ee129027, replyNumber=0, likeNumber=80, createdTime=2016-08-31, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e56ee129027, moduleTitle=诺华抗癌药Jakavi达真性红细胞增多症III期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e56ee129027)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996928, encodeId=aec01996928da, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=TECOS心血管安全性研究达到主要终点, objectType=article, longId=52145, objectId=726252145e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=726252145e0, replyNumber=0, likeNumber=80, createdTime=2016-03-05, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=726252145e0, moduleTitle=TECOS心血管安全性研究达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=726252145e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996929, encodeId=0d7f1996929e5, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=艾滋病复方新药F/TAF在III期临床达主要终点，有望成为标准治疗方案, objectType=article, longId=55957, objectId=68175595eff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68175595eff, replyNumber=0, likeNumber=30, createdTime=2016-02-17, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68175595eff, moduleTitle=艾滋病复方新药F/TAF在III期临床达主要终点，有望成为标准治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68175595eff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996922, encodeId=730f1996922f1, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=吉利德丙肝新药Sovaldi日本III期试验达主要终点, objectType=article, longId=33000, objectId=3fca33000a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fca33000a7, replyNumber=0, likeNumber=73, createdTime=2014-09-06, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fca33000a7, moduleTitle=吉利德丙肝新药Sovaldi日本III期试验达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fca33000a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996918, encodeId=0fd71996918a8, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=诺华Jakavi III期试验达主要终点, objectType=article, longId=31686, objectId=87cd3168624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87cd3168624, replyNumber=0, likeNumber=64, createdTime=2014-12-30, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87cd3168624, moduleTitle=诺华Jakavi III期试验达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87cd3168624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996919, encodeId=8a58199691957, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=默沙东Isentress大规模III期研究达主要终点, objectType=article, longId=31742, objectId=ba9a31e42bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba9a31e42bc, replyNumber=0, likeNumber=72, createdTime=2014-04-30, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba9a31e42bc, moduleTitle=默沙东Isentress大规模III期研究达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba9a31e42bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996920, encodeId=153419969200c, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=拜耳多吉美（Nexavar）肝癌III期未达主要终点, objectType=article, longId=31832, objectId=f1413183272, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1413183272, replyNumber=0, likeNumber=62, createdTime=2014-04-25, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1413183272, moduleTitle=拜耳多吉美（Nexavar）肝癌III期未达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1413183272)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996921, encodeId=6b5b1996921c1, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=安进PCSK9抑制剂evolocumab III期TESLA达主要终点, objectType=article, longId=32022, objectId=e7cc32022c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7cc32022c7, replyNumber=0, likeNumber=74, createdTime=2014-04-15, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7cc32022c7, moduleTitle=安进PCSK9抑制剂evolocumab III期TESLA达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7cc32022c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

主要终点

2020-05-29

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

ImmunoGen的抗体 - 药物偶联物Mirvetuximab soravtansine未达到III期卵巢癌研究的主要终点

2019-03-03

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

NEJM：无转移生存可以作为前列腺癌新药审批的主要终点(SPARTAN研究)

2019-01-10

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Vertex制药表示VX-659三联疗法治疗囊肿性纤维化的III期研究达到了主要终点

2019-09-30

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

阿斯利康狼疮药物anifrolumab未能到达三期临床试验的主要终点

2018-12-23

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

RedHill的RHB-104完成了克罗恩病治疗的主要终点

2019-02-17

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

大冢制药的guadecitabine未达到一线治疗AML的III期研究的主要终点

2018-08-11

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Keytruda治疗头颈癌三期临床试验未达主要终点(Keynote-040研究)

2018-05-26

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

膀胱癌药物3期临床达主要终点

2018-01-18

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点

2017-08-03

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

阿斯利康复方抗生素Zavicefta达医院获得性肺炎III期临床主要终点

2016-10-05

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

艾滋病新复方药3期临床试验达主要终点

2017-11-08

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

阿斯利康心血管药Brilinta未能达到新适应症III期临床主要终点

2017-02-27

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

诺华抗癌药Jakavi达真性红细胞增多症III期临床主要终点

2016-08-31

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

TECOS心血管安全性研究达到主要终点

2016-03-05

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

艾滋病复方新药F/TAF在III期临床达主要终点，有望成为标准治疗方案

2016-02-17

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

吉利德丙肝新药Sovaldi日本III期试验达主要终点

2014-09-06

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

诺华Jakavi III期试验达主要终点

2014-12-30

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

默沙东Isentress大规模III期研究达主要终点

2014-04-30

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

拜耳多吉美（Nexavar）肝癌III期未达主要终点

2014-04-25

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

安进PCSK9抑制剂evolocumab III期TESLA达主要终点

2014-04-15

科室
- - 订阅+
  - 更多科室
工具
服务